What is NWE's current stock price?

As of now, NWE is trading at $60.88, with a daily change of +2.72%.

What are the risks associated with NWE stock?

NWE Key risk is its Low Risk Level, .

What is NWE next earnings date?

NWE next earnings report is scheduled for Oct 28, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NWE Stock Analysis & IQ Rating | NorthWestern Corpora

NWE

NorthWestern Corpora

$60.88

+$1.61 | +2.72%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 60.9

MKT CAP

$ 3.74B

52W Low

$ 50.43

VOL

$ 250.16K

P/E Ratio

16.58

AVG VOL

$ 355.98K

RSI

69.35

TREND

Uptrend

NWE Stock IQ

Login to see NorthWestern Corpora (NWE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NWE Target Price

Login to display

Strengths

NWE Rewards

Earnings are forecast to grow

NWE Rewards

Trading below its fair value

Chart

$57.43 (+6.01%)

$52.54 (+15.87%)

$55.33 (+10.03%)

$52.58 (+15.79%)

1year

6month

3month

1month

NWE Risk Level

NWE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Low volume

LOW

HIGH

NWE Analysts Opinion

NWE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

NWE Analysts Opinion

NWE Analysts opinion is negative and it remained unchanged from the past 3 months

NWE Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

94%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

NWE Street Opinion

NWE Street view is extremely bullish and have positive views on the near-term outlook

NWE Performance Sentiment

Sentiments overview associated with NWE events and the stock performance.

94%

6%

Positive

Negative

15 out of 16
events present

1 out of 16
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$59.27

Resistance
Price

$56.34

Current Price Range

$59.27

Show methods +

NWE Earnings

The TTM reflects 12-month period, providing review of NWE financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

1,528

1,514

1,422

+3.66%

Cost of Revenue

631

662

641

-0.78%

Gross Profit

897

852

781

+7.17%

Operating Exp

551

529

481

+7.03%

Operating Inc

345

323

300

+7.24%

Net Interest Inc

-142

-132

-115

-

Interest Exp

142

132

115

+11.12%

Other Inc Exp

17

23

16

+3.08%

EPS Growth

3.85

3.65

3.22

+9.35%

NWE Financial Health

The company financial health has shown minor improvement, but significant issues remain

Financial Score

3.44

Next Earnings Date: Oct 28, 2025

NWE Latest Analysis +

Industry Leaders Join Ingenio Cares Mission to Redefine Access Coordination and Value in United States Healthcare. OAK BROOK Ill. Oct. 17 2025 (GLOBE NEWSWIRE) -- Ingenio Care Inc. an AI-driven digital health company today announced the expansion of its distinguished Advisory Board bringing together renowned clinical and business leaders to help guide its next phase of growth. The move reflects Ingenio Care'.s continued momentum in building a connected AI-enabled healthcare network that impr

Fri Oct 17, 2025

$59.27 | +0.30%

Activity

Simergent Announces FDA Clearance of the Archimedes™ Home Dialysis System. Archimedes™ a novel automated peritoneal dialysis system which is now FDA 510(k)-cleared enables bloodless dialysis for End Stage Kidney Disease (ESKD) patients in the home or clinic setting. Following a successful human factors usability study affiliated with Northwestern University...

Tue Oct 14, 2025

$58.33 | +1.74%

Activity

Bruker Corporation (BRKR) Secures $10M Order for Nuclear Magnetic Resonance Instrumentation. Bruker Corporation (NASDAQ:BRKR) is one of the top stocks in Michael Burrys stock portfolio. On October 3 the company confirmed it had received new orders for advanced Nuclear Magnetic Resonance instrumentation. The $10 million order is from the New York Structural Biology Center (NYSBC) the University of Delaware and Northwestern University. The advanced Nuclear Magnetic [….]

Mon Oct 13, 2025

$57.33 | -0.66%

Activity

TEM Expands Partnership With Northwestern Medicine Amid AI Boom. Tempus AI deepens its collaboration with Northwestern Medicine embedding its AI co-pilot David directly into the health systems EHR to boost clinical efficiency.

Fri Oct 10, 2025

$57.71 | -1.03%

Activity

Bruker secures $10M in federally funded NMR orders from NYSBC Delaware and Northwestern.

Fri Oct 3, 2025

$57.73 | +1.23%

Activity

The Zacks Analyst Blog Highlights Atmos Energy Consolidated Water NorthWestern Energy and Northwest Natural. As economic uncertainty grows ATO CWCO NWE and NWN offer low-beta stability attractive dividends and steady growth making them defensive picks in the utility sector.

Thu Oct 2, 2025

$57.03 | -0.90%

Potential

BLRX: A Venture into GBM. By In a highly anticipated event BioLineRx Ltd. (NASDAQ:BLRX) announced a deal to develop a new cancer drug in a joint venture with . Hemispherian is an Oslo Norway-based private biotechnology company developing new cancer therapies. Its lead asset is GLIX1 a first-in-class small-molecule therapeutic targeting DNA repair vulnerabilities in cancer cells. The JV has been established for the development clinical evaluation and commercialization of GLIX1 where Hemispherian

Tue Sep 30, 2025

$58.61 | +0.86%

Activity

Potential

FAQ About NWE Stock Insights

What is NWE current stock price?

What are NWE stock strengths?

What risks are associated with NWE stock?

When is NWE next earnings report?

What is NWE market cap and volume?

What is NWE's current Stock IQ?

Should I buy NWE stock right now?

Is NWE a Strong Buy right now?

What does a 'Strong Buy' rating mean for NWE?

What does a 'Strong Sell' rating mean for NWE?

What factors influence NWE's Stock IQ?

Explore our NWE Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NWE Stock Strategies
Effective Risk Management

FIND US ON

Receive our NWE Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NWE

NorthWestern Corpora

Current Price

$60.88

+$1.61 | +2.72%

52W High

$ 60.9

MKT CAP

$ 3.74B

52W Low

$ 50.43

VOL

$ 250.16K

P/E Ratio

16.58

AVG VOL

$ 355.98K

RSI

69.35

TREND

Uptrend

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

NWE Rewards

Earnings are forecast to grow

NWE Rewards

Trading below its fair value

NWE Stock IQ

Login to unlock NorthWestern Corpora (NWE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$57.43 (+6.01%)

$52.54 (+15.87%)

$55.33 (+10.03%)

$52.58 (+15.79%)

1year

6month

3month

1month

NWE Analysts Opinion

NWE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

NWE Analysts Opinion

NWE Analysts opinion is negative and it remained unchanged from the past 3 months

NWE Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

94%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

NWE Street Opinion

NWE Street view is extremely bullish and have positive views on the near-term outlook

NWE Risk Level

NWE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Low volume

LOW

HIGH

NWE Performance Sentiment

Sentiments overview associated with NWE events and the stock performance.

94%

6%

Positive

Negative

15 out of 16
events present

1 out of 16
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$59.27

Resistance
Price

$56.34

Current Price Range

$59.27

Show methods +

NWE Earnings

The TTM data reflects the most recent 12-month period, providing overview of NWE financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

1,528

1,514

1,422

+3.66%

Cost of Revenue

631

662

641

-0.78%

Gross Profit

897

852

781

+7.17%

Operating Exp

551

529

481

+7.03%

Operating Inc

345

323

300

+7.24%

Net Interest Inc

-142

-132

-115

-

Interest Exp

142

132

115

+11.12%

Other Inc Exp

17

23

16

+3.08%

EPS Growth

3.85

3.65

3.22

+9.35%

NWE Financial Health

The company financial health has shown minor improvement, but significant issues remain

Financial Score

3.44

Next Earnings Date: Oct 28, 2025

NWE Latest Analysis

Industry Leaders Join Ingenio Cares Mission to Redefine Access Coordination and Value in United States Healthcare. OAK BROOK Ill. Oct. 17 2025 (GLOBE NEWSWIRE) -- Ingenio Care Inc. an AI-driven digital health company today announced the expansion of its distinguished Advisory Board bringing together renowned clinical and business leaders to help guide its next phase of growth. The move reflects Ingenio Care'.s continued momentum in building a connected AI-enabled healthcare network that impr

Fri Oct 17, 2025

$59.27 | +0.30%

Activity

Simergent Announces FDA Clearance of the Archimedes™ Home Dialysis System. Archimedes™ a novel automated peritoneal dialysis system which is now FDA 510(k)-cleared enables bloodless dialysis for End Stage Kidney Disease (ESKD) patients in the home or clinic setting. Following a successful human factors usability study affiliated with Northwestern University...

Tue Oct 14, 2025

$58.33 | +1.74%

Activity

Bruker Corporation (BRKR) Secures $10M Order for Nuclear Magnetic Resonance Instrumentation. Bruker Corporation (NASDAQ:BRKR) is one of the top stocks in Michael Burrys stock portfolio. On October 3 the company confirmed it had received new orders for advanced Nuclear Magnetic Resonance instrumentation. The $10 million order is from the New York Structural Biology Center (NYSBC) the University of Delaware and Northwestern University. The advanced Nuclear Magnetic [….]

Mon Oct 13, 2025

$57.33 | -0.66%

Activity

TEM Expands Partnership With Northwestern Medicine Amid AI Boom. Tempus AI deepens its collaboration with Northwestern Medicine embedding its AI co-pilot David directly into the health systems EHR to boost clinical efficiency.

Fri Oct 10, 2025

$57.71 | -1.03%

Activity

Bruker secures $10M in federally funded NMR orders from NYSBC Delaware and Northwestern.

Fri Oct 3, 2025

$57.73 | +1.23%

Activity

The Zacks Analyst Blog Highlights Atmos Energy Consolidated Water NorthWestern Energy and Northwest Natural. As economic uncertainty grows ATO CWCO NWE and NWN offer low-beta stability attractive dividends and steady growth making them defensive picks in the utility sector.

Thu Oct 2, 2025

$57.03 | -0.90%

Potential

BLRX: A Venture into GBM. By In a highly anticipated event BioLineRx Ltd. (NASDAQ:BLRX) announced a deal to develop a new cancer drug in a joint venture with . Hemispherian is an Oslo Norway-based private biotechnology company developing new cancer therapies. Its lead asset is GLIX1 a first-in-class small-molecule therapeutic targeting DNA repair vulnerabilities in cancer cells. The JV has been established for the development clinical evaluation and commercialization of GLIX1 where Hemispherian

Tue Sep 30, 2025

$58.61 | +0.86%

Activity

Potential

Discover NWE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NWE. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NWE Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NWE Stock trends

NWE Stock performance

NWE Stock analysis

NWE investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NWE

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NWE

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

NWE Stock Analysis & IQ Rating | NorthWestern Corpora

NWE Stock IQ

NWE Target Price

NWE Risk Level

NWE Analysts Opinion

NWE Street Consensus

NWE Performance Sentiment

Technical Price Levels

NWE Financial Health

Explore our NWE Stock insights

Receive our NWE Daily Alerts

NWE Stock IQ

NWE Street Consensus

NWE Risk Level

Technical Price Levels

Discover NWE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NWE. We're here to help you make informed investment decisions today.

Receive our NWE Daily Alerts

NWE Runner Alarm